{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-217455","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2021-07-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.816720+00:00","generated_at":"2026-06-30T04:53:41.690868+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Janux Therapeutics increases CEO base salary to $500k, bonus target to 50%","bullets":["CEO David Campbell's annual base salary increased from $424,408 to $500,000 effective July 15, 2021.","Annual target performance bonus percentage increased from 40% to 50%, retroactive to beginning of 2021.","Changes approved by Board of Directors upon Compensation Committee recommendation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-217455","json":"https://secwatch.observer/filing/0001193125-21-217455.json","markdown":"https://secwatch.observer/filing/0001193125-21-217455.md","text":"https://secwatch.observer/filing/0001193125-21-217455.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000119312521217455/0001193125-21-217455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000119312521217455/d139884d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T04:53:41.690868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}